May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
Bringing Drugs to Market Costs Less Than Previously Thought, Study Finds
MACRA Survey Finds Oncology Physicians Unprepared for Payment Changes
Companies Continue to Face Challenges With Developing CAR-T Treatment
Healthy, but Still Hurting: Challenges of Cancer Survivorship
Dr Charlie Fazio on Balancing Different Delivery and Payment Models